| Symbol | PMN |
|---|---|
| Name | PROMIS NEUROSCIENCES INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | Canada |
| Telephone | 416-847-6898 |
| Fax | — |
| — | |
| Website | https://www.promisneurosciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001374339 |
| Description | ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimers disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinsons disease, and dementia with Lewy bodies. It primarily operates in Canada. Additional info from NASDAQ: |
New Form S-8 - ProMIS Neurosciences Inc. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 0001104659-26-068268 <b>Size:</b> 387 KB
Read moreDirector WYMAN WILLIAM W 🟢 acquired 16.5K shares (2 derivative) of ProMIS Neurosciences Inc. (PMN) at $10.77 Transaction Date: May 20, 2026 | Filing ID: 065775
Read moreDirector Williams Eugene 🟢 acquired 16.5K shares (2 derivative) of ProMIS Neurosciences Inc. (PMN) at $10.77 Transaction Date: May 20, 2026 | Filing ID: 065774
Read moreDirector Warma Neil K 🟢 acquired 160.0K shares (1 derivative) of ProMIS Neurosciences Inc. (PMN) at $10.77 ($1.7M) Transaction Date: May 20, 2026 | Filing ID: 065772
Read moreDirector Shafmaster Madge K. 🟢 acquired 16.5K shares (2 derivative) of ProMIS Neurosciences Inc. (PMN) at $10.77 Transaction Date: May 20, 2026 | Filing ID: 065771
Read moreDirector Cashman Neil 🟢 acquired 50.0K shares (1 derivative) of ProMIS Neurosciences Inc. (PMN) at $10.77 Transaction Date: May 20, 2026 | Filing ID: 065769
Read moreMilbury Max A. 🟢 acquired 18.2K shares (1 derivative) of ProMIS Neurosciences Inc. (PMN) at $10.77 Transaction Date: May 20, 2026 | Filing ID: 065766
Read moreDirector Mandel-Brehm Josh 🟢 acquired 16.5K shares (2 derivative) of ProMIS Neurosciences Inc. (PMN) at $10.77 Transaction Date: May 20, 2026 | Filing ID: 065763
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06750432 | PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) | Phase1 | Alzheimer Disease, Early Onset | Active_Not_Recruiting | 2024-12-13 | 2026-12-01 | ClinicalTrials.gov |
| NCT06105528 | A Phase 1a Study of PMN310 In Healthy Volunteers | Phase1 | Healthy Participants | Completed | 2023-11-18 | 2024-07-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06105528 |
| PMN310 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06105528 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease, Early Onset | ACTIVE_NOT_RECRUITING | NCT06750432 |
| PMN310 | Other | Phase PHASE1 | Alzheimer Disease, Early Onset | ACTIVE_NOT_RECRUITING | NCT06750432 |
| Placebo | DRUG | Phase PHASE1 | Alzheimer Disease, Early Onset | ACTIVE_NOT_RECRUITING | NCT06750432 |
| PMN310 | DRUG | Phase PHASE1 | Alzheimer Disease, Early Onset | ACTIVE_NOT_RECRUITING | NCT06750432 |